Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: A cross-sectional study

BMC Pulmonary Medicine

Volumn 10, Issue , 2010, Pages

  Dennis, Rodolfo J ^a,c   Maldonado, Dario ^b   Rojas, Maria X ^c   Aschner, Pablo ^d   Rondón, Martin ^c   Charry, Laura ^c   Casas, Alejandro ^b  

^a FUNDACIÓN CARDIOINFANTIL INSTITUTO DE CARDIOLOGÍA   (Colombia)

^b FUNDACIÓN NEUMOLÓGICA COLOMBIANA   (Colombia)

^c PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^d Association Colombiana de Diabetes   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; FIBRINOGEN; HEMOGLOBIN A1C; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SPIROMETRY; BLOOD; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IMMUNOLOGY; INFLAMMATION; LUNG DISEASE; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FERRITINS; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INFLAMMATION; INTERLEUKIN-6; LUNG DISEASES; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954885721     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-10-38     Document Type: Article

References (26)

1. Yeh HC, Punjabi NM, Wang NY, Pankow JS, Duncan BB, Cox CE, Selvin E, Brancati FL. Cross-sectional and prospective study of lung function in adults with type 2 diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 2008, 31:828-832. 10.2337/dc07-1464, 18375433.
2. Walter RE, Beiser A, Givelber RJ, O'Connor GT, Gottlieb DJ. Association between glycemic state and lung function. Am J Respir Crit Care Med 2003, 167:911-916. 10.1164/rccm.2203022, 12623860.
3. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among US Adults. Diabetes Care 1999, 22:1978-1983. 10.2337/diacare.22.12.1978, 10587829.
4. Schmidt MI, Duncan BB, Sharret AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 1999, 353:1649-1652. 10.1016/S0140-6736(99)01046-6, 10335783.
5. Dahl M, Vestbo G, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive Protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:250-255. 10.1164/rccm.200605-713OC, 17053205.
6. Davis WA, Knuiman M, Kendall P, Grange V, Davis TME. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes. Diabetes Care 2004, 27:752-757. 10.2337/diacare.27.3.752, 14988297.
7. Asociación Latinoamericana de Diabetes 2001, Guías ALAD 2000. Rev Asoc Latinoam Diab; supl 1: Edición extraordinaria, Asociación Latinoamericana de Diabetes.
8. Rodriguez N, Rojas MX, Guevara DP, Dennis RJ, Maldonado D. Generación de valores de referencia para la evaluación de la espirometria: Estudio en una población colombiana. Acta Med Colomb 2002, 27(6):389-397.
9. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978, 118(6 Pt 2):1-120.
10. American Thoracic Society Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991, 144(5):1202-1218. American Thoracic Society.
11. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32(1):193-203. 10.2337/dc08-9025, 2606813, 18945920.
12. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999, 159:179-187.
13. Rojas MX, Dennis R. Valores de referencia para parámetros espirométricos en la población adulta residente en Bogotá, DC, Colombia. Biomédica 2010, 30(1):82-94.
14. Litonjua AA, Lazarus R, Sparrow D, DeMolles D, Weiss ST. Lung function in type 2 diabetes: the normative aging study. Respiratory Medicine 2005, 99:1583-1590. 10.1016/j.rmed.2005.03.023, 16291079.
15. McKeever TM, Weston PJ, Hubbard R, Fogarty A. Lung function and glucose metabolism: an analysis of data from from the third national health and nutrition examination survey. Am J Epidemiol 2005, 161:546-556. 10.1093/aje/kwi076, 15746471.
16. Chance WW, Rhee C, Yilmaz C, Dane DM, Pruneda ML, Raskin P, Hsia CC. Diminished alveolar microvascular reserves in type 2 diabetes reflect systemic microangiopathy. Diabetes Care 2008, 31(8):1596-1601. 10.2337/dc07-2323, 2494655, 18492945.
17. Bronwlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820. 10.1038/414813a, 11742414.
18. Ozsahin K, Tuqrul A, Mert S, Yüksel M, Tuqrul G. Evaluation of pulmonary alveolo-capillary permeability in type 2 diabetes mellitus: using technetium 99 mTc-DTPA aerosol scintigraphy and carbon monoxide diffusion capacity. Journal of Diabetes and its Complications 2006, 20:205-209. 10.1016/j.jdiacomp.2005.07.003, 16798470.
19. Hsia CCW, Raskin P. Lung involvement in Diabetes: does it matter?. Diabetes Care 2008, 31:828-829. 10.2337/dc08-0103, 18375433.
20. Fabri LM, Rabbe KF. From COPD to chronic inflammatory syndrome?. Lancet 2007, 370:797-799. 10.1016/S0140-6736(07)61383-X, 17765529.
21. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle age cohort. Thorax 2008, 63:599-605. 10.1136/thx.2007.088112, 18245145.
22. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164:1008-1011.
23. Moller DE. Potential role of TNF alpha in the pathogenesis of insulin resistance and type II diabetes. Trends Endocrinol Metab 2000, 11:212-217. 10.1016/S1043-2760(00)00272-1, 10878750.
24. Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Paré PD. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med 2000, 163:469-473.
25. Ford ES, Mannino DM. Prospective association between lung function and the incidence of diabetes. Diabetes Care 2004, 27:2966-2970. 10.2337/diacare.27.12.2966, 15562215.
26. Fehrenbach H, Kasper M, Tshernig T, Shearman MS, Schuh D, Müller M. Receptor for advanced glycation endproducts exhibits highly differential cellular and subcellular localization in rat and human lung. Cell Mol Biol 1998, 44:1147-1157.